← Back to patent-cliff list
BI-3034701
Tier C — Watch / tradeBI-3034701
Boehringer Ingelheim International Gmbh
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Overweight, Obesity
Regional status
US
Phase II
2026-06-30
EU
Phase II
2026-06-30
China
Phase II
2026-06-30
Japan
Phase I
2026-07-21
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BI-3034701?
Approved indications include: Overweight, Obesity.
When does the BI-3034701 patent expire?
No public expiry year is available for BI-3034701 yet; this page updates once verified.
How do I get a quote for BI-3034701 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29